Humacyte HUMA
NASDAQ HUMA
$0.41 +0.00 (+0.80%)
As of: Oct 22, 2026 · 3:40 PM EDT

Humacyte (HUMA) Net Margin (2020 - 2026)

Updated

Humacyte (HUMA) reported Net Margin of -9064.53% for Q2 2026, up 3446.43 percentage points from -12510.96% a year earlier but down 5505.14 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) Net Margin (2020 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Humacyte's Net Margin came in at -4560.82%, up 2610.45 percentage points year-over-year; for FY2025, it was -2003.58%.

  • Five-year quarterly Net Margin spans a low of -13096.68% in Q3 2021 and a high of 7570.41% in Q1 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -3559.39% (Q1 2026), -5311.35% (Q4 2025) and -2325.37% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,170.46 Bn 1,139.04 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 648.38 Bn 568.24 Bn 17.30 Bn 0.83%
3 AbbVie 504.43 Bn 477.54 Bn 12.70 Bn 21.27%
4 Merck 367.73 Bn 322.11 Bn 12.21 Bn -8.04%
5 Novartis Ag 303.35 Bn 267.34 Bn 11.24 Bn 22.65%
6 Astrazeneca 268.20 Bn 241.88 Bn 12.86 Bn 16.30%
7 Amgen 242.55 Bn 197.95 Bn 7.24 Bn 23.62%
8 Gilead Sciences 194.80 Bn 169.00 Bn 6.22 Bn -134.51%
9 Pfizer 173.31 Bn 119.95 Bn 10.94 Bn -1.65%
10 Humacyte 96.06 Mn -102.38 Mn -825,000.00 -9,064.53%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9,064.53%
Mar 31, 2026 -3,559.39%
Dec 31, 2025 -5,311.35%
Sep 30, 2025 -2,325.37%
Jun 30, 2025 -12,510.96%
Mar 31, 2025 7,570.41%
Sep 30, 2021 -13,096.68%
Sep 30, 2020 -4.48%
API Access

Humacyte Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=HUMA&period=max&api_key=YOUR_API_KEY